Drying temperature-dependent profile of bioactive compounds and prediction of antioxidant capacity of cashew apple pomace using coupled Gaussian Process Regression and Support Vector Regression (GPR-SVR) model.

Crude extracts from cashew apple pomace (CAP) dried at different temperatures were used in High-Pressure Liquid Chromatography to quantify total alkaloids content (TAC), total flavanoids content (TFC), total saponin content (TSC) and total phenolics content (TPC). Diphenyl-1-picrylhydrazyl (DPPH) was used to determine the antioxidant capacity (AOC) of CAP. Fourier-Transformed Infrared Spectroscopy-Attenuated Total Reflectance (FTIR-ATR) was used to identify the functional groups present in the pomace. TAC, TFC, TSC and TPC were used as inputs to model AOC using Gaussian Process Regression (GPR), and Support Vector Regression (SVR) and a coupled model was developed using the residuals of GPR and SVR. It was found that increasing drying temperature decreased TAC, TFC, TPC and AOC but TSC increased. Both GPR and SVR predicted AOC with high accuracy. Drying CAP at lower temperature preserved more bioactive compounds hence high AOC; FTIR-ATR showed that CAP has good hydration capacity and contains majorly inorganic phosphates, aliphatic hydrocarbons and primary alcohols. Model coupling enhanced AOC prediction.

Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.

The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area (LGA) prevalence of 23% (range 4-62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by community drug distributors over the intervention period. Reported treatment coverage for each round was ≥85% of the treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage (72.2%; 95% CI 65.5-79.0%). To determine impact on transmission, we monitored three LF infection parameters (microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in 2009, when SVs had been treated for 7-10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to 0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia ≥1% and/or L3 stages in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of >25%. Longer or additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for 'hot spots' where transmission is ongoing.